Table 1.

Demographics, Hematologic malignancy, chemotherapy regimen prior to diagnosis, stem cell transplant status, and absolute lymphocyte count at diagnosis.

Patient	Demographics	Hematologic Malignancy	Chemotherapy Regimen (within 30 days of diagnosis)	Transplant status	Absolute Lymphocyte count at diagnosis
Patient-1	75 M	Multiple Myeloma	melphalan	Autologous SCT	870
Patient-2	67F	AML	None	Allogeneic SCT	N/A
Patient-3	65M	Atypical CML	hydroxyurea & ruxolitinib	None	N/A
Patient-4	30M	AML	busulfan & fludarabine	Allogeneic SCT	380
Patient-5	29M	Classical Hodgkin's Lymphoma	None	None	N/A
Patient-6	49M	CML	ponatinib	None	160
Patient-7	49F	B-Cell ALL	vincristine & dasatinib	None	1050
Patient-8	53F	B-Cell ALL	rituximab	Allogeneic SCT	110
Patient-9	65M	CLL	acalabrutinib	None	N/A
Patient-10	30F	AML	None	None	800
Patient-11	26F	CML	Negative for COVID-19	None	0
Patient-12	42F	Classical Hodgkin's Lymphoma	None	None	N/A
Patient-13	86M	AML	imatinib	None	N/A
Patient-14	53F	Amyloidosis	bortezomib	Autologous SCT	N/A
Patient-15	67M	AML	ibrutinib	Allogeneic SCT	330
Patient-16	57F	CLL	ibrutinib	None	2560
Patient-17	38M	DLBCL	rituximab	Allogeneic SCT	N/A
Patient-18	35F	Classical Hodgkin's Lymphoma	None	None	540
Patient-19	59F	B-Cell ALL	rituximab, cytarabine, methotrexate, imatinib,	None	530
Patient-20	84F	CML	imatinib	None	510
Patient-21	71M	Multiple Myeloma	lenalidomide	Autologous SCT	N/A
Patient-22	64M	T-Cell ALL	venetoclax, cyclophosphamide, vincristine	None	260
Patient-23	24M	AML	None	None	590
Patient-24	61M	Multiple Myeloma	daratumumab	None	N/A
Patient-25	65M	CMML	decitabine	None	N/A
Patient-26	58F	Multiple Myeloma	bortezomib	Autologous SCT	N/A
Patient-27	45M	Follicular Lymphoma	rituximab & acalabrutinib	None	N/A
Patient-28	72F	Multiple Myeloma	None	Autologous SCT	640
Patient-29	52M	Classical Hodgkin's Lymphoma	None	None	N/A
Patient-30	55F	APML	None	None	1820
Patient-31	65F	MGUS	None	None	980
Patient-32	82M	Multiple Myeloma	daratumumab & lenalidomide	None	N/A
Patient-33	74M	Multiple Myeloma	lenalidomide	Autologous SCT	400
Patient-34	72M	Multiple Myeloma	lenalidomide	Autologous SCT	N/A
Patient-35	49F	CML	None	Allogeneic SCT	2640
Patient-36	24F	AML	None	None	N/A
Patient-37	65M	B-Cell ALL	rituximab, cytarabine, methotrexate, imatinib	None	N/A
Patient-38	54M	Multiple Myeloma	daratumumab & carfilzomib	None	2430
Patient-39	60M	Multiple Myeloma	bortezomib & lenalidomide	Autologous SCT	N/A
Patient-40	73M	Multiple Myeloma	lenalidomide	Autologous SCT	N/A
Patient-41	62M	APML	arsenic trioxide & all-trans retinoic acid	None	N/A
Patient-42	62F	T-Cell Lymphoma	None	Autologous SCT	N/A
Patient-43	55M	Amyloidosis	cyclophosphamide, bortezomib	None	780
Patient-44	59M	Follicular Lymphoma	bendamustine & obinatuzumab	None	50
Patient-45	78F	CML	dasatinib	None	1090
Patient-46	76F	MDS	lenalidomide	None	N/A
Patient-47	78M	T-Cell PLL	None	Autologous SCT	70
Patient-48	55F	Smoldering Multiple Myeloma	None	None	N/A
Patient-49	58F	CLL	None	None	N/A
Patient-50	56M	DLBCL	None	None	N/A
Patient-51	70F	DLBCL	rituximab, methotrexate, procarbazine, vincristine	None	630
Patient-52	81M	AML	decitabine & venetoclax	None	270
Patient-53	60M	Multiple Myeloma	daratumumab	Autologous SCT	N/A

SCT, stem cell transplant; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; DLBCL, diffuse large B-Cell lymphoma; MDS, myelodysplastic syndrome; PLL, prolymphocytic leukemia; NS, nodular sclerosing hodgkin's lymphoma; APML, acute promyelocytic leukemia; MGUS, monoclonal gammopathy of undetermined significance.